|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GAB1 |
Gene summary for GAB1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GAB1 | Gene ID | 2549 |
| Gene name | GRB2 associated binding protein 1 | |
| Gene Alias | DFNB26 | |
| Cytomap | 4q31.21 | |
| Gene Type | protein-coding | GO ID | GO:0001525 | UniProtAcc | Q13480 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2549 | GAB1 | CCI_1 | Human | Cervix | CC | 2.34e-07 | 8.98e-01 | 0.528 |
| 2549 | GAB1 | CCI_2 | Human | Cervix | CC | 7.88e-05 | 6.14e-01 | 0.5249 |
| 2549 | GAB1 | CCI_3 | Human | Cervix | CC | 6.07e-08 | 6.02e-01 | 0.516 |
| 2549 | GAB1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 8.07e-25 | -7.16e-01 | 0.0155 |
| 2549 | GAB1 | HTA11_5212_2000001011 | Human | Colorectum | AD | 3.94e-02 | -6.37e-01 | -0.2061 |
| 2549 | GAB1 | HTA11_5216_2000001011 | Human | Colorectum | SER | 4.73e-02 | -3.92e-01 | -0.1462 |
| 2549 | GAB1 | HTA11_7696_3000711011 | Human | Colorectum | AD | 4.90e-09 | -3.98e-01 | 0.0674 |
| 2549 | GAB1 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.14e-15 | -5.47e-01 | 0.294 |
| 2549 | GAB1 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 2.08e-51 | 3.84e+00 | 0.281 |
| 2549 | GAB1 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 3.42e-07 | -6.39e-01 | 0.2585 |
| 2549 | GAB1 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 2.22e-13 | -5.24e-01 | 0.3005 |
| 2549 | GAB1 | F007 | Human | Colorectum | FAP | 5.08e-04 | -4.02e-01 | 0.1176 |
| 2549 | GAB1 | A002-C-010 | Human | Colorectum | FAP | 9.74e-03 | -1.43e-01 | 0.242 |
| 2549 | GAB1 | A001-C-207 | Human | Colorectum | FAP | 3.45e-04 | -2.77e-01 | 0.1278 |
| 2549 | GAB1 | A015-C-203 | Human | Colorectum | FAP | 4.19e-38 | -5.67e-01 | -0.1294 |
| 2549 | GAB1 | A015-C-204 | Human | Colorectum | FAP | 1.35e-06 | -3.32e-01 | -0.0228 |
| 2549 | GAB1 | A014-C-040 | Human | Colorectum | FAP | 6.57e-05 | -4.62e-01 | -0.1184 |
| 2549 | GAB1 | A002-C-201 | Human | Colorectum | FAP | 2.64e-23 | -6.24e-01 | 0.0324 |
| 2549 | GAB1 | A002-C-203 | Human | Colorectum | FAP | 1.09e-05 | -2.34e-01 | 0.2786 |
| 2549 | GAB1 | A001-C-119 | Human | Colorectum | FAP | 5.75e-15 | -7.18e-01 | -0.1557 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00071738 | Cervix | CC | epidermal growth factor receptor signaling pathway | 36/2311 | 108/18723 | 1.04e-08 | 8.44e-07 | 36 |
| GO:00603267 | Cervix | CC | cell chemotaxis | 73/2311 | 310/18723 | 2.82e-08 | 1.96e-06 | 73 |
| GO:00381278 | Cervix | CC | ERBB signaling pathway | 37/2311 | 121/18723 | 8.57e-08 | 4.88e-06 | 37 |
| GO:00315328 | Cervix | CC | actin cytoskeleton reorganization | 31/2311 | 107/18723 | 3.34e-06 | 8.99e-05 | 31 |
| GO:19016538 | Cervix | CC | cellular response to peptide | 72/2311 | 359/18723 | 1.89e-05 | 3.48e-04 | 72 |
| GO:00434349 | Cervix | CC | response to peptide hormone | 77/2311 | 414/18723 | 1.40e-04 | 1.70e-03 | 77 |
| GO:00713757 | Cervix | CC | cellular response to peptide hormone stimulus | 57/2311 | 290/18723 | 2.32e-04 | 2.59e-03 | 57 |
| GO:00328698 | Cervix | CC | cellular response to insulin stimulus | 42/2311 | 203/18723 | 4.95e-04 | 4.83e-03 | 42 |
| GO:00328688 | Cervix | CC | response to insulin | 50/2311 | 264/18723 | 1.28e-03 | 1.02e-02 | 50 |
| GO:00082865 | Cervix | CC | insulin receptor signaling pathway | 25/2311 | 116/18723 | 3.59e-03 | 2.30e-02 | 25 |
| GO:19013423 | Cervix | CC | regulation of vasculature development | 60/2311 | 348/18723 | 4.48e-03 | 2.72e-02 | 60 |
| GO:00457653 | Cervix | CC | regulation of angiogenesis | 59/2311 | 342/18723 | 4.73e-03 | 2.83e-02 | 59 |
| GO:0038127 | Colorectum | AD | ERBB signaling pathway | 55/3918 | 121/18723 | 1.19e-09 | 8.85e-08 | 55 |
| GO:0007173 | Colorectum | AD | epidermal growth factor receptor signaling pathway | 50/3918 | 108/18723 | 3.08e-09 | 2.07e-07 | 50 |
| GO:0032868 | Colorectum | AD | response to insulin | 91/3918 | 264/18723 | 2.02e-07 | 8.48e-06 | 91 |
| GO:1901653 | Colorectum | AD | cellular response to peptide | 114/3918 | 359/18723 | 8.32e-07 | 2.88e-05 | 114 |
| GO:0032869 | Colorectum | AD | cellular response to insulin stimulus | 72/3918 | 203/18723 | 1.10e-06 | 3.68e-05 | 72 |
| GO:0071375 | Colorectum | AD | cellular response to peptide hormone stimulus | 95/3918 | 290/18723 | 1.50e-06 | 4.66e-05 | 95 |
| GO:0043434 | Colorectum | AD | response to peptide hormone | 126/3918 | 414/18723 | 2.70e-06 | 7.86e-05 | 126 |
| GO:0031532 | Colorectum | AD | actin cytoskeleton reorganization | 41/3918 | 107/18723 | 2.81e-05 | 5.28e-04 | 41 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0520516 | Cervix | CC | Proteoglycans in cancer | 60/1267 | 205/8465 | 9.13e-08 | 1.18e-06 | 7.00e-07 | 60 |
| hsa0401210 | Cervix | CC | ErbB signaling pathway | 28/1267 | 85/8465 | 2.40e-05 | 1.82e-04 | 1.08e-04 | 28 |
| hsa0472214 | Cervix | CC | Neurotrophin signaling pathway | 32/1267 | 119/8465 | 5.01e-04 | 2.42e-03 | 1.43e-03 | 32 |
| hsa0510020 | Cervix | CC | Bacterial invasion of epithelial cells | 23/1267 | 77/8465 | 6.25e-04 | 2.93e-03 | 1.73e-03 | 23 |
| hsa0522510 | Cervix | CC | Hepatocellular carcinoma | 40/1267 | 168/8465 | 1.52e-03 | 6.39e-03 | 3.78e-03 | 40 |
| hsa052119 | Cervix | CC | Renal cell carcinoma | 20/1267 | 69/8465 | 2.07e-03 | 8.17e-03 | 4.83e-03 | 20 |
| hsa040142 | Cervix | CC | Ras signaling pathway | 51/1267 | 236/8465 | 3.55e-03 | 1.34e-02 | 7.91e-03 | 51 |
| hsa0520517 | Cervix | CC | Proteoglycans in cancer | 60/1267 | 205/8465 | 9.13e-08 | 1.18e-06 | 7.00e-07 | 60 |
| hsa0401213 | Cervix | CC | ErbB signaling pathway | 28/1267 | 85/8465 | 2.40e-05 | 1.82e-04 | 1.08e-04 | 28 |
| hsa0472215 | Cervix | CC | Neurotrophin signaling pathway | 32/1267 | 119/8465 | 5.01e-04 | 2.42e-03 | 1.43e-03 | 32 |
| hsa05100110 | Cervix | CC | Bacterial invasion of epithelial cells | 23/1267 | 77/8465 | 6.25e-04 | 2.93e-03 | 1.73e-03 | 23 |
| hsa0522513 | Cervix | CC | Hepatocellular carcinoma | 40/1267 | 168/8465 | 1.52e-03 | 6.39e-03 | 3.78e-03 | 40 |
| hsa0521114 | Cervix | CC | Renal cell carcinoma | 20/1267 | 69/8465 | 2.07e-03 | 8.17e-03 | 4.83e-03 | 20 |
| hsa0401411 | Cervix | CC | Ras signaling pathway | 51/1267 | 236/8465 | 3.55e-03 | 1.34e-02 | 7.91e-03 | 51 |
| hsa05100 | Colorectum | AD | Bacterial invasion of epithelial cells | 44/2092 | 77/8465 | 1.13e-09 | 2.22e-08 | 1.42e-08 | 44 |
| hsa04722 | Colorectum | AD | Neurotrophin signaling pathway | 50/2092 | 119/8465 | 2.28e-05 | 2.24e-04 | 1.43e-04 | 50 |
| hsa05205 | Colorectum | AD | Proteoglycans in cancer | 70/2092 | 205/8465 | 1.37e-03 | 8.46e-03 | 5.39e-03 | 70 |
| hsa05225 | Colorectum | AD | Hepatocellular carcinoma | 59/2092 | 168/8465 | 1.50e-03 | 8.69e-03 | 5.54e-03 | 59 |
| hsa05211 | Colorectum | AD | Renal cell carcinoma | 28/2092 | 69/8465 | 2.58e-03 | 1.37e-02 | 8.75e-03 | 28 |
| hsa04012 | Colorectum | AD | ErbB signaling pathway | 31/2092 | 85/8465 | 1.02e-02 | 3.91e-02 | 2.50e-02 | 31 |
| Page: 1 2 3 4 5 6 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GAB1 | SNV | Missense_Mutation | rs761657658 | c.1100N>T | p.Ser367Leu | p.S367L | Q13480 | protein_coding | tolerated(0.16) | benign(0.003) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| GAB1 | SNV | Missense_Mutation | c.1697N>C | p.Ile566Thr | p.I566T | Q13480 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A2-A0YT-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | arimidex | SD | |
| GAB1 | SNV | Missense_Mutation | c.1229G>A | p.Arg410Gln | p.R410Q | Q13480 | protein_coding | tolerated(0.32) | probably_damaging(0.997) | TCGA-BH-A18I-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR | |
| GAB1 | SNV | Missense_Mutation | c.1720G>C | p.Glu574Gln | p.E574Q | Q13480 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-EK-A2RJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| GAB1 | SNV | Missense_Mutation | c.2155N>T | p.Pro719Ser | p.P719S | Q13480 | protein_coding | tolerated(0.06) | benign(0.436) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| GAB1 | SNV | Missense_Mutation | rs374885566 | c.256G>T | p.Asp86Tyr | p.D86Y | Q13480 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-AA-3854-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| GAB1 | SNV | Missense_Mutation | novel | c.683N>A | p.Ser228Asn | p.S228N | Q13480 | protein_coding | tolerated(0.41) | benign(0.003) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| GAB1 | SNV | Missense_Mutation | rs201202756 | c.325N>T | p.Arg109Cys | p.R109C | Q13480 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| GAB1 | SNV | Missense_Mutation | c.2096N>A | p.Ala699Asp | p.A699D | Q13480 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| GAB1 | SNV | Missense_Mutation | c.979N>G | p.Thr327Ala | p.T327A | Q13480 | protein_coding | tolerated(0.29) | benign(0.001) | TCGA-AD-A5EJ-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |